(Public, NASDAQ:TSRO)   Watch this stock  
Find more results for Merck Sharp & Dohme Corp
-0.79 (-0.85%)
Real-time:   2:23PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 90.54 - 94.00
52 week 29.51 - 94.01
Open 93.01
Vol / Avg. 444,318.00/1.85M
Mkt cap 4.74B
P/E     -
Div/yield     -
EPS -7.28
Shares 49.36M
Beta 1.62
Inst. own 107%
Aug 4, 2016
Q2 2016 TESARO Inc Earnings Call - 4:15PM EDT - Add to calendar
Aug 4, 2016
Q2 2016 TESARO Inc Earnings Release - 4:00PM EDT - Add to calendar
Jun 4, 2016
TESARO Inc Investor and Analyst Briefing
May 13, 2016
TESARO Inc Annual Shareholders Meeting (Estimated)
May 11, 2016
TESARO Inc Annual Shareholders Meeting
May 5, 2016
Q1 2016 TESARO Inc Earnings Call - Webcast
May 5, 2016
Q1 2016 TESARO Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -29565.80% -79308.52%
Operating margin -28302.28% -74461.20%
EBITD margin - -73503.16%
Return on average assets -121.51% -96.85%
Return on average equity -293.79% -238.38%
Employees 119 -
CDP Score - -


1000 Winter St Ste 3300
WALTHAM, MA 02451-1230
United States - Map
+1-339-9700900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform. It offers VARUBI (rolapitant), which is an oral substance P/neurokinin 1 (NK-1) receptor antagonist for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. It is developing IV formulation of rolapitant, which has completed various Phase 1 clinical trials. Its niraparib is an orally active and poly (ADP-ribose) polymerase (PARP) inhibitor. Its immuno-oncology platform has immuno-oncology programs, which include TSR-022 and TSR-042.

Officers and directors

David M. Mott Independent Chairman of the Board
Age: 50
Bio & Compensation  - Reuters
Mary Lynne Hedley Ph.D. President, Chief Operating Officer, Director
Age: 52
Bio & Compensation  - Reuters
Leon O. Moulder Jr. Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Timothy R. Pearson Chief Financial Officer, Executive Vice President
Age: 47
Bio & Compensation  - Reuters
Joseph L. Farmer Senior Vice President, General Counsel, Secretary
Age: 44
Bio & Compensation  - Reuters
Martin Huber M.D. Senior Vice President and Chief Medical Officer
Bio & Compensation  - Reuters
Kavita Patel M.D. Director
Bio & Compensation  - Reuters
James O. Armitage M.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Garry A Nicholson Independent Director
Bio & Compensation  - Reuters
Arnold L. Oronsky Ph.D. Independent Director
Age: 76
Bio & Compensation  - Reuters